BioSpace News Archive

The biotech is laying off about 29% of its employees and will focus its resources on the company’s hypoimmune platform. The latest downsizing follows a previous round of layoffs in August 2023.

An increase in funding share and available lab space helps to keep the Bay State’s biotech and pharma sectors strong.

Following the recommendations of an independent Data Monitoring Committee, Novo Nordisk has halted a Phase III kidney outcomes study of semaglutide ahead of schedule due to strong efficacy signals.

The next frontier in RNA therapies, RNA editing has the potential to treat both genetic and common disorders, and the technology is rapidly expanding beyond the liver.

The European Commission on Thursday ordered Illumina to divest Grail, opening the next chapter in the years-long regulatory saga. Illumina is reviewing the order, Reuters reported.

The MeiraGTx founder and CEO, now on her third career, didn’t take a typical path.

The subcutaneous version of its blockbuster multiple sclerosis drug notched a victory in a key late-stage study. Roche will submit the OCARINA II data to global health authorities in the coming months.

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, shares the invitation for the company’s Capital Markets Day on October 17, 2023.

Genentech, a member of the Roche Group, announced results from the Phase IV CHIMES trial evaluating Ocrevus® in Black and Hispanic / Latinx people with relapsing multiple sclerosis.

Data from the ongoing Phase II open-label extension (OLE) study of evobrutinib show sustained clinical efficacy and a safety profile that remains consistent with that previously reported over five years of therapy - the longest follow-up of any Bruton’s tyrosine kinase inhibitor (BTKi) in multiple sclerosis (MS) studies Additional Phase II OLE data show significant and clinically meaningful improvements on mental health and quality of life measures in study participants with relapsing